{"id":"W3087401339","doi":"10.1200/jco.20.02110","title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Population; Oncology; Melanoma; Lymph node; Cancer; Stage (stratigraphy); Surgery; Gastroenterology; Pathology; Immunotherapy; Confidence interval; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002964508,0.0006767326,0.001517465,0.0002425684,0.0003129707,0.0007067026,0.0005152156,0.0007429743,0.002133112],"category_scores_gemma":[0.00153558,0.000311714,0.001749208,0.0003076838,0.000474733,0.0005273663,0.0002603371,0.001312064,0.0002903147],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004160019,"about_ca_system_score_gemma":0.0004872114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005466474,"about_ca_topic_score_gemma":0.001405769,"domain_scores_codex":[0.9990311,0.0005760078,0.00007889445,0.0001311585,0.00008903463,0.0000938747],"domain_scores_gemma":[0.998968,0.0002418873,0.0004164526,0.0001495022,0.00005000365,0.0001741105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9055096,0.003625661,0.02136957,0.0006880417,0.00390516,0.0001323682,0.00008667253,0.001008003,0.01173477,0.0001036671,0.001353327,0.05048332],"study_design_scores_gemma":[0.5970857,0.2226575,0.157936,0.0001664073,0.009050687,0.0005881687,0.00008273585,0.001792954,0.004066456,0.0005592008,0.005943413,0.0000707031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920249,0.004930741,0.0004151768,0.0001989807,0.0001092937,0.0004359124,0.0008238095,0.00002590827,0.001035406],"genre_scores_gemma":[0.9958634,0.001142115,0.0003493089,0.0003490101,0.0001544013,0.000397452,0.001051778,0.000005977299,0.000686417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002964508,"threshold_uncertainty_score":0.01567805,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1106583319210831,"score_gpt":0.3944431596250101,"score_spread":0.2837848277039271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}